HuiTai Biomedicine is a leading biotech company that develops novel therapeutics for the treatment of Fibrotic Diseases and creates TGF-β therapeutics based on the precise and targeted regulation of TGF-β signaling.
At present, the developing novel drug for the treatment of Idiopathic Pulmonary Fibrosis (IPF) is targeted regulation of TGF-β signaling, and there is no similar competitive product in the world. The drug has now completed the pre-clinical research (GMP production and GLP safety assessment), and we are going to submit the application of first-in-class new drug clinical trial to FDA and NMPA.
